Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Astellas-Maxygen Joint Venture Highlights Japan's Creative Alliances - BIO Asia Conference

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Astellas, like most top-tier Japanese pharmaceutical companies, has been aggressive in its out-licensing in the past year, and its 2009 joint venture with Maxygen highlights how Japanese companies are using creative deals to stay competitive
Advertisement

Related Content

Astellas Increases R&D To Bridge Prograf, Flomax Patent Losses
Astellas Increases R&D To Bridge Prograf, Flomax Patent Losses
Astellas Signs Strategic Oncology Partnership With Ambit After Medivation Success
Maxygen And Astellas Form Joint Venture, Combining Cash And Staff
Maxygen And Astellas Form Joint Venture, Combining Cash And Staff
Advertisement
UsernamePublicRestriction

Register

SC074153

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel